Form 4: Zoetis CEO Kristin Peck Reports RSU Vesting & Stock Sale

Sentiment:

Insider Transaction Report 23 February 2026 4:31 PM

Zoetis Inc. CEO Kristin Peck reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

Kristin C. Peck, Zoetis Inc.'s Chief Executive Officer and Director, reported changes in her beneficial ownership of company common stock.
On February 19, 2026, 7,354 shares of common stock were acquired due to the vesting and settlement of restricted stock units (RSUs).
Following this acquisition, 108,691 shares of common stock were directly owned.
Concurrently, 3,623 shares of common stock were disposed of at a price of $127.28 per share, likely to cover tax obligations related to the RSU vesting.
After the disposition, 105,068 shares of common stock were directly owned.
Additionally, 833.6435 common stock equivalents were held indirectly in the Zoetis Inc. Savings Plan (401(k)) as of December 31, 2025.
The filing also details remaining unvested Restricted Stock Units, including 14,708, 28,072, and 5,556 units, which represent contingent rights to receive common stock upon future vesting dates.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and expected insider transaction related to executive compensation. The vesting of RSUs is a positive sign of compensation realization, and the subsequent sale for tax purposes is standard practice, not indicative of negative sentiment.

Positives

The vesting of Restricted Stock Units indicates the achievement of performance or service conditions by the CEO.
The CEO continues to hold a significant number of shares (105,068 directly, plus 833.6435 indirectly), demonstrating continued alignment with shareholder interests.

Negatives

A disposition of 3,623 shares occurred, which, while common for tax purposes upon RSU vesting, represents a reduction in direct ownership.

Future Outlook

Industry Context

StockSavvy.ai notes that insider transaction filings like this Form 4 are routine disclosures for executives receiving equity compensation. The vesting of RSUs and subsequent 'sell to cover' for taxes is a common practice and generally does not indicate a change in management's outlook on the company's prospects, especially when a significant portion of equity is retained.

Comparison to Industry Standards

This transaction aligns with standard executive compensation practices in the pharmaceutical and animal health industries, where Restricted Stock Units (RSUs) are a common component of long-term incentive plans.
Companies like Eli Lilly (LLY), Merck (MRK), and IDEXX Laboratories (IDXX) also frequently utilize RSU grants for their executives, with similar vesting schedules and tax-related dispositions upon settlement.
The retention of a substantial equity stake by the CEO post-vesting is typical for executives in well-established, large-cap companies, indicating continued alignment with shareholder value creation.

Stakeholder Impact

Shareholders: The CEO's continued significant equity ownership aligns her interests with shareholders. The transaction itself is a routine compensation event.
Employees: The RSU vesting demonstrates the company's commitment to its equity compensation plans, which can be a positive for employee morale and retention.

Next Steps

Future vesting of remaining Restricted Stock Units on their respective anniversary dates (e.g., one-third of RSUs granted Feb 19, 2025, will vest on their anniversaries).
Future vesting of remaining Restricted Stock Units on their respective anniversary dates (e.g., one-third of RSUs granted Feb 18, 2026, will vest on their anniversaries).
Future vesting of remaining Restricted Stock Units on their respective anniversary dates (e.g., one-third of RSUs granted Feb 6, 2024, will vest on their anniversaries).

Key Dates

Date	Description
2024-02-06	Grant date for RSUs, one-third of which vest on the first, second, and third anniversaries.
2025-02-19	Grant date for RSUs, one-third of which vest on the first, second, and third anniversaries.
2025-12-31	Date as of which common stock equivalents were held in the Zoetis Inc. Savings Plan (401(k)).
2026-02-18	Grant date for RSUs, one-third of which will vest on the first, second, and third anniversaries.
2026-02-19	Transaction date for the acquisition of common stock upon RSU vesting and disposition of shares.
2026-02-23	Signature date of the Form 4 filing.

Recommendation

hold

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and a subsequent 'sell to cover' transaction for tax purposes. It does not provide new fundamental information about Zoetis Inc.'s operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The CEO retains a substantial equity stake, which is a positive for alignment, but the transaction itself is neutral in terms of immediate investment implications. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Zoetis, ZTS, Kristin Peck, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, CEO, Director, Equity Compensation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.